mRNA Anticancer Vaccine
Oncology
Preclinical ResearchActive
Key Facts
About Sunshine Biopharma
Sunshine Biopharma's mission is to develop novel therapeutics for cancer and life-threatening diseases. Its key achievement is establishing a hybrid business model, combining revenue-generating generic drug sales in Canada with proprietary R&D focused on overcoming chemotherapy resistance and developing mRNA vaccines. The company's strategy is to use the cash flow from its commercial subsidiary to fund the advancement of its oncology pipeline, mitigating the financial volatility typical of early-stage biotechs. Its lead program, SBFM-PL4, represents a novel approach to a long-standing challenge in oncology.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Bendamustine Intermediate | AR Life Science | Commercial |